Effects of intravenous lysine acetylsalicylate versus oral aspirin on platelet responsiveness in patients with ST-segment elevation myocardial infarction: the ECCLIPSE-STEMI trial

David Vivas1 · José Julio Jiménez2 · Roberto Martín-Asenjo3 · Esther Bernardo1 · María Aranzazu Ortega-Pozzi1 · Juan Carlos Gómez-Polo1 · Guillermo Moreno3 · Isidre Vilacosta1 · Julián Pérez-Villacastín1 · Antonio Fernández-Ortiz1

Accepted: 20 November 2022 / Published online: 8 December 2022
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022

Abstract
Prasugrel and ticagrelor, new P2Y12-ADP receptor antagonists, are associated with greater pharmacodynamic inhibition and reduction of cardiovascular events in patients with an acute coronary syndrome. However, evidence is lacked about the effects of achieving faster and stronger cyclooxygenase inhibition with intravenous lysine acetylsalicylate (LA) compared to oral aspirin. Recently, we demonstrated in healthy volunteers that the administration of intravenous LA resulted in a significantly reduction of platelet reactivity compared to oral aspirin. Loading dose of LA achieves platelet inhibition faster, and with less variability than aspirin. However, there are no data of this issue in patients with an ST-segment elevation myocardial infarction (STEMI). This is a prospective, randomized, multicenter, open platelet function study conducted in STEMI patients. Subjects were randomly assigned to receive a loading dose (LD) of intravenous LA 450 mg plus oral ticagrelor 180 mg, or LD of aspirin 300 mg plus ticagrelor 180 mg orally. Platelet function was evaluated at baseline, 30 min, 1 h, 4 h and 24 h using multiple electrode aggregometry and vasodilator-stimulated phosphoprotein phosphorylation (VASP). The primary endpoint of the study is the inhibition of platelet aggregation (IPA) after arachidonic acid (AA) 0.5 mM at 30 min. Secondary endpoints were the IPA at 1, 4, and 24 h after AA, and non-AA pathways through the sequence (ADP and TRAP). A total of 32 STEMI patients were randomized (16 LA, 16 aspirin). The inhibition of platelet aggregation after AA 0.5 mM at 30 min was greater in subjects treated with LA compared with aspirin: 166 vs. 412 respectively (p = 0.001). This differential effect was observed at 1 h (p = 0.01), but not at 4 and 24 h. Subjects treated with LA presented less variability and faster inhibition of platelet aggregation wit AA compared with aspirin. The administration of intravenous LA resulted in a significantly reduction of platelet reactivity compared to oral aspirin on ticagrelor inhibited platelets in patients with STEMI. Loading dose of LA achieves an earlier platelet inhibition, and with less variability than aspirin.

Trial Registration: Unique identifier: NCT02929888; URL: http://www.clinicaltrials.gov

Keywords Platelets · Lysine acetylsalicylate · Aspirin · Acute coronary syndrome

Highlights

- Antiplatelet therapy plays a key role in patients with ST-segment elevation myocardial infarction (STEMI)
- Although potent P2Y12-ADP receptor inhibitor-drugs have shown a reduction in cardiovascular outcomes in this scenario, evidence is lacked about achieving faster cyclooxygenase inhibition
- The results of our study suggest that, compared with oral aspirin, intravenous lysine acetylsalicylate significantly
achieved an earlier platelet inhibition in STEMI patients, with less variability
• Larger studies are warranted to assess whether this strategy could decrease cardiovascular ischemic events in this scenario

Introduction

In patients with an acute coronary syndrome (ACS), platelets play a key role, particularly in the early phases of the disease [1, 2]. Activated platelets release thromboxane A₂ (TXA₂), adenosine diphosphate (ADP) and adenosine triphosphate (ATP), stimulating platelet activation and aggregation processes [3]. Thus, antiplatelet therapy is the cornerstone of treatment for patients with coronary artery disease [4]. Currently, the combination of aspirin, an irreversible inhibitor of cyclooxygenase (COX) and a P2Y12-ADP receptor inhibitor, is the antiplatelet treatment of choice in patients with ACS, where a fast and strong platelet inhibition is needed [5, 6]. Although prasugrel and ticagrelor have shown a better profile than clopidogrel by reducing cardiovascular outcomes in patients with ACS [7–11], evidence is lacked about achieving faster and stronger COX inhibition. In fact, current guidelines of management of ACS only recommend loading dose of oral non-enteric-coated aspirin (162–325 mg), and intravenous use only when oral ingestion is not possible [5, 6].

Lysine acetylsalicylate (LA) is a soluble salt that, shortly after being administered, is converted into acetylsalicylic acid, which is metabolized in the liver to salicylic acid (active form) [12, 13]. LA presents potent antiplatelet compound with fewer gastrointestinal adverse effects than aspirin and has the unique property of being able to be administered both orally and intravenously [14]. Some studies have compared aspirin with LA in both, healthy volunteers and patients with stable coronary artery disease, and showed similar or higher effectiveness on platelet inhibition with LA [15, 16]. Recently, it has demonstrated that the administration of intravenous LA resulted in a significantly reduction of platelet reactivity compared with aspirin orally in healthy volunteers; moreover, LA achieves faster platelet inhibition, and with less intra- and interindividual variability than aspirin [17]. However, there is no data about this finding in the setting of ST-segment elevation acute myocardial infarction (STEMI) patients, where early platelet inhibition could be associated with a reduction in cardiovascular events [18–20].

Therefore, the present study aims to analyze the effects of combined administration of intravenous LA versus aspirin orally on platelet aggregation, and to assess whether the administration of these different drug regimens affect the time to onset of platelet inhibition.

Methods

Patient population

The ECCLIPSE-STEMI (“Impact of intravenous Lysing Acetylsalicylate versus oral Aspirin on in Patients with ST-segment Elevation Myocardial Infarction”, www.controlled-trials.com number NCT02929888) trial was a prospective, randomized, multicenter, open, pharmacodynamic platelet function study in patients with an acute myocardial infarction. Patients were enrolled if they were ≥ 18 years-old and were admitted with a diagnosis of STEMI by the emergency units, defined by an episode of chest pain or equivalent symptoms, associated to ECG typical disorder (persistent elevation of ST-segment ≥ 1 mm in frontal leads, or ≥ 2 mm in precordial leads in at least 2 adjoining leads; or new onset left bundle branch block). Exclusion criteria included: known allergies to aspirin, clopidogrel, prasugrel or ticagrelor, cardiogenic shock or hemodynamic instability, recent antiplatelet therapy (< 14 days), including nonsteroidal anti-inflammatory drugs (NSAIDs.), oral anticoagulation, any active bleeding or blood dyscrasias, recent gastrointestinal bleeding (< 6 months prior to inclusion), recent history of stroke or intracranial bleeding (< 6 months prior to inclusion), known anemia, thrombocytopenia or severe chronic kidney/liver disease, any known active neoplasm, or pregnant females. The study complied with the Declaration of Helsinki and it was approved by the Ethical Committee of the San Carlos University Hospital [21]. All patients gave their written informed consent to participate in the study. A clinical research organization (CRO) was contracted to hold the data and perform the data analysis after data lock. An independent data safety monitoring committee was instituted for adjudication of adverse clinical events.

Study design and randomization

Patients were randomly allocated in a 1:1 fashion to receive 450 mg intravenous LA or 300 mg of oral aspirin (non-enteric coated formulation). Both groups will receive routine care in the setting of the STEMI clinical practice guidelines, including concomitant administration of a potent P2Y12 ADP-receptor inhibitor: ticagrelor (this drug was selected because it is the P2Y12 ADP-receptor inhibitor available in our emergency care setting). Blood samples will be extracted at baseline (before the administration of antithrombotic drugs), at 30 min, 1, 4, and at 24 h so as to measure platelet function. All subjects underwent standard cardiology care including, unless contraindicated, primary percutaneous coronary intervention (PCI). Use of glycoprotein (GP) IIb/IIIa inhibitors and choice of anticoagulant were left to the criteria of the treating physician.
Concomitant treatments, such as beta-blockers, angiotensin-converting enzyme inhibitors and statins were used according to current clinical guidelines [5, 6]. The ECCLIPSE-STEMI trial started including patients in June 2017, and recruitment were extended until December 2020 due to COVID-19 pandemic situation.

**Platelet function testing**

Blood samples were collected from an antecubital vein using a 21-gauge needle into 5 ml plastic tubes containing hirudin (25μg/mL) after randomization and each of the previously specified set time points. First 3 ml of blood were discharged to avoid spontaneous platelet activation. All samples were processed within 1 h by researchers that were blinded to the treatment assigned.

**Platelet aggregation**

Platelet aggregation were assessed using multiple electrode aggregometry (MEA), in whole blood with the Multiplate™ analyzer (Roche Diagnostics, Basel, Switzerland) as previously described [22]. This instrument assesses the change in impedance caused by the adhesion of platelets onto sensor units formed by silver-covered electrodes. Curves were recorded for 6 min, and platelet aggregation was determined as area under the curve of arbitrary aggregation units (AU*min). In the present investigation, 0.5 mM arachidonic acid (AA) were used to evaluate COX inhibition, 6.4 μM ADP was used as agonist to evaluate P2Y12 inhibitors responsiveness, and thrombin receptor-activated peptide (TRAP) 32 μM were used to stimulate thrombin-dependent platelet aggregation. Inhibition of platelet aggregation (IPA) was defined as the relative percent decrease in maximal aggregation and was calculated as [(baseline aggregation response—aggregation at the different timepoints of the study)/baseline aggregation response] × 100.

**Platelet P2Y12 reactivity index (PRI)**

The PRI was determined through assessment of vasodilator stimulated phosphoprotein (VASP) phosphorylation according to standard protocols [23]. In brief, VASP phosphorylation was measured by quantitative flow cytometry (Gallios cytometer Beckman Coulter, Miami, Florida) using commercially available labeled monoclonal antibodies (Biocytex Inc., Marseille, France). The PRI was calculated after measuring the mean fluorescence intensity (MFI) of VASP phosphorylation levels following challenge with prostaglandin E1 (PGE1) and prostaglandin E1 plus ADP. PGE1 increases VASP phosphorylation levels through stimulation of adenylyl cyclase, while ADP binding to purinergic receptors leads to the inhibition of adenylyl cyclase. Therefore, the addition of ADP to prostaglandin E1-stimulated platelets reduces levels of prostaglandin E1-induced VASP phosphorylation. PRI = [(MFI PGE1) − (MFI PGE1 + ADP)/(MFI PGE1)] × 100. Elevated PRI values are indicative of upregulation of the P2Y12 signaling pathway.

**Endpoints and sample size**

The primary endpoint of the study was the inhibition platelet aggregation (IPA) responses to AA stimuli 30 min after administration of study drugs. Secondary endpoints were the IPA at 1, 4 and 24 h after AA, and non-AA pathways through the sequence. Another secondary endpoints were the cardiovascular outcomes (death, reinfarction, stroke) and bleeding events during admission. To estimate the sample size, and according to previous pharmacodynamics studies, we hypothesized a 27% mean reduction in the primary endpoint following treatment with intravenous LA compared with oral aspirin [15–17]. Therefore, at least 60 subjects would be required to provide a 80% power to detect statistical differences between groups with a two-sided α level of 0.05. Given that the effect size found was larger than initially considered for the primary objective, the contrast finally had sufficient power (more than 85%) to detect differences with an n = 16 size in each group.

**Statistical analysis**

Endpoints were analyzed for all recruited patients in an intention to treat analysis. Statistical analysis will be performed by an independent investigator, blinded to the study group assignment. Variables were analyzed for a normal distribution with the Kolmogorov–Smirnov test. Normally distributed variables are presented as mean ± standard deviation and were compared using the Student t test. Variables that did not follow a normal distribution are presented as median and interquartile range and were compared with the Mann–Whitney U test. Categorical variables are expressed as frequencies and percentages and were compared with the χ2 test or the Fisher exact test when at least 25% of values showed an expected cell frequency below 5. Confidence intervals (CI) and all test of statistical significance for treatment comparisons were evaluated at a two-tailed significance level of 0.05. All analyses of platelet function were conducted in all randomized subjects who received at least one dose of study drug. Statistical analysis was performed using SPSS/PC 17 (SPSS Inc. Chicago, Illinois).
Results

Patient population

A total of 32 patients with STEMI were randomized (16 in intravenous LA group and 16 in oral aspirin group). Baseline demographics, clinical characteristics, laboratory data and angiographic findings of both groups are shown in Table 1. There were no significant differences between groups. Table 2 shows in-hospital management and cardiovascular outcomes, and no differences were found between LA and aspirin group.

Platelet function profiles

There were no differences in platelet function at baseline between intravenous LA plus ticagrelor and oral aspirin plus ticagrelor groups with all platelet function test assessed (Table 3). Platelet reactivity at 30 min after AA 0.5 mM was significantly lower in patients treated with intravenous LA compared with oral aspirin: 166.0 (64.5–247.0) vs. 412.0 (241.0–589.0), p = 0.001. These results were observed at 1 h [148.0 (86.0–188.5) vs. 221.0 (170.0–311.0), p = 0.013], but not at 4 h and 24 h. Figure 1 shows IPA with AA 0.5 mM at any time points.
Platelet function profiles according to P2Y12-dependent pathway and thrombin-dependent platelet aggregation were tested with ADP 6.4 μM and TRAP 32 μM respectively. There were no differences between intravenous LA and oral aspirin groups at any time points (p = NS). These results were similar when exploring platelet activation with PRI.

Figure 2 shows individual subject antiplatelet response after AA 0.5 mM at baseline, 30 min, 1, 4 and 24 h. Subjects treated with LA presented less variability and faster decrease in platelet inhibition compared with aspirin group.

Discussion

Antiplatelet therapy plays a pivotal role in the management of STEMI patients. Current practical guidelines recommend in these patients the combination of aspirin and a P2Y12 inhibitor (preferably prasugrel/ticagrelor than clopidogrel, if no contraindicated) [6]. Specifically, and according to these recommendations, aspirin should be given orally including chewing, or intravenous (if oral ingestion is not possible) to ensure complete inhibition of thromboxane A2-dependent platelet aggregation. However, it is unclear whether the administration of intravenous antiplatelet in this scenario leads to a better prognosis [24]. This is the first randomized trial to analyze the pharmacodynamic effects of intravenous LA compared to aspirin orally in patients with STEMI. In particular, the results of the study show that intravenous LA was associated with higher platelet inhibition than oral aspirin group. Further, the administration of intravenous LA resulted in a rapid and marked reduction on platelet reactivity by 30 min compared to oral aspirin. Finally, LA achieved a more consistent platelet inhibition and less inter- and intraindividual variability.

Interestingly, the results of our study were consistent with previous report in healthy volunteers [17]. Thus, the STEMI scenario is associated with a prothrombotic and inflammation state, and an early platelet inhibition reveals as a key role in the treatment of acute coronary disease. Despite of this unfavorable situation, patients treated with intravenous LA showed faster platelet inhibition. Due to a lower sample size, the study was not designed to detect differences in cardiovascular outcomes, and more studies are needed to know whether a faster platelet inhibition in STEMI patients could be associated with a reduction in cardiovascular events [18–20].

It has been hypothesized that LA not only reduces platelet reactivity when COX pathway was assessed, but also showed and early and faster reduction with other platelet inhibition receptors [17]. Although in healthy volunteers intravenous LA compared with oral aspirin showed a significant reduction in thrombin-dependent platelet pathway aggregation, the ECCLIPSE-STEMI trial did not find significant differences in any stage of the analysis.

Current investigation concentrates on the field of P2Y<sub>12</sub>-ADP platelet receptor inhibition. Prasugrel and ticagrelor are characterized by more prompt, potent and predictable antiplatelet effects and greater clinical efficacy than clopidogrel [10, 11]. However, these drugs also present limitations, including a delayed antiplatelet effect, particularly in the setting of STEMI. In the ECCLIPSE-STEMI trial, all patients were treated with loading dose of ticagrelor 180 mg, and differences in platelet reactivity were shown despite a faster ADP-P2Y12 inhibition. Therefore, these findings show that, despite of a high ticagrelor platelet inhibition, intravenous LA could reduce platelet reactivity faster than aspirin, which could have clinical implications.

Other intravenous antiplatelet agents have been assessed in the setting of the ACS, such as Glycoprotein IIb/IIIa inhibitors or cangrelor [25–27]. However, current STEMI clinical guidelines did not recommend the routine use of these drugs, and only cangrelor could be considered in patients not pre-treated with oral P2Y12 inhibitors at the time of primary percutaneous coronary intervention [6]. In the ECCLIPSE-STEMI trial, only 5 patients (2 in LA and 3 in aspirin group) received downstream intravenous abciximab, none of them in the first 60 min after study drug

### Table 2 In-hospital management and adverse outcomes according to treatment group

|                        | Lysine acetylsalicylate (n = 16) | Aspirin (n = 16) | p-value |
|------------------------|----------------------------------|-----------------|---------|
| Coronary revascularization procedures, n (%) | | | |
| Primary PCI            | 15 (93.8)                       | 14 (87.5)       | NS      |
| CABG                   | 0 (0.0)                         | 1 (6.3)         | NS      |
| No revascularization   | 1 (6.3)                         | 1 (6.3)         | NS      |
| Drug therapy during hospitalization, n (%) | | | |
| GP IIb/IIa inhibitors  | 2 (12.5)                        | 3 (18.8)        | NS      |
| Unfractioned heparin   | 14 (87.5)                       | 13 (81.3)       | NS      |
| Enoxaparin             | 2 (12.5)                        | 3 (18.8)        | NS      |
| Beta-blockers          | 16 (100.0)                      | 15 (93.8)       | NS      |
| ACE inhibitors/ARB     | 12 (75.0)                       | 11 (68.8)       | NS      |
| Statins                | 16 (100.0)                      | 16 (100.0)      | NS      |
| Adverse in-hospital outcomes, n (%) | | | |
| Death                  | 0 (0.0)                         | 0 (0.0)         | N/A     |
| Stent thrombosis       | 0 (0.0)                         | 1 (6.3)         | NS      |
| Ventricular arrhythmias| 1 (6.3)                         | 0 (0.0)         | NS      |
| Cardiogenic shock      | 1 (6.3)                         | 2 (12.5)        | NS      |
| Complete AV block      | 1 (6.3)                         | 1 (6.3)         | NS      |
| Major bleeding         | 1 (6.3)                         | 1 (6.3)         | NS      |

ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker, AV auriculo-ventricular; CABG coronary artery bypass graft; GP glycoprotein, IQR interquartile range, NS non-significant, PCI percutaneous coronary intervention
Table 3  Platelet function profiles according to treatment assigned

|                  | Lysine acetylsalicylate (n = 16) | Aspirin (n = 16) | p-value |
|------------------|----------------------------------|-----------------|---------|
| **AA 0.5 mM (%)** |                                  |                 |         |
| Baseline PR      | 635.0 (334.0–10.009.0)           | 574.0 (390.0–805.0) | 0.802   |
| 30 min PR        | 166.0 (64.5–247.0)               | 412.0 (241.0–589.0) | 0.001   |
| 1 h PR           | 148.0 (86.0–188.5)               | 221.0 (170.0–311.0) | 0.013   |
| 4 h PR           | 124.0 (23.0–129.0)               | 81.5 (60.0–93.0)  | 0.774   |
| 24 h PR          | 107.0 (46.0–180.0)               | 147.5 (92.0–211.0) | 0.228   |
| **ADP 6.4 μM (%)** |                                  |                 |         |
| Baseline PR      | 351.5 (221.5–683.0)              | 507.0 (313.0–700.0) | 0.464   |
| 30 min PR        | 313.0 (214.0–499.0)              | 419.0 (290.5–598.0) | 0.609   |
| 1 h PR           | 232.5 (166.5–452.5)              | 351 (188.0–478.0) | 0.407   |
| 4 h PR           | 154.0 (122.3–255.0)              | 127.5 (114.0–204.0) | 0.391   |
| 24 h PR          | 152.0 (93.0–213.0)               | 137.5 (89.0–191.0) | 0.827   |
| **TRAP 32 μM (%)** |                                  |                 |         |
| Baseline PR      | 678.0 (387.5–904.0)              | 805.0 (651.0–947.0) | 0.272   |
| 30 min PR        | 617.0 (481.0–758.0)              | 874 (819.0–1023.0) | 0.057   |
| 1 h PR           | 826.0 (598.0–964.5)              | 729.0 (568.0–961.0) | 0.733   |
| 4 h PR           | 462.0 (266.0–731.0)              | 630.5 (435.0–727.0) | 0.568   |
| 24 h PR          | 520.0 (320.5–797.0)              | 561.5 (303.0–710.0) | 0.820   |
| **PRI (%)**      |                                  |                 |         |
| Baseline         | 71.8 (48.8–76.8)                 | 71.9 (56.1–80.7)  | 0.864   |
| 30 min           | 55.8 (46.8–80.9)                 | 67.8 (55.1–82.4)  | 0.492   |
| 1 h              | 23.0 (14.6–82.1)                 | 39.4 (6.4–88.2)   | 0.868   |
| 4 h              | 22.4 (10.6–29.8)                 | 17.3 (6.5–30.5)   | 0.423   |
| 24 h             | 14.4 (1.36–34.8)                 | 13.8 (4.1–25.4)   | 0.843   |

Values are median (interquartile range). AA arachidonic acid. ADP adenosin diphosphate. IPA inhibition of platelet aggregation. TRAP thrombin receptor-activated peptide. PR platelet reactivity. PRI platelet P2Y12 reactivity index.

Fig. 1  Mean inhibition of platelet aggregation (IPA) responses to Arachidonic Acid (AA) 0.5 mM at timeline 0 (baseline), 30 min, 1 h, 4 h, and 24 h after Lysine Acetylsalicylate 450 mg iv (n = 16), or Aspirin 300 mg orally (n = 16)
administration. The effect of Glycoprotein IIb/IIIa inhibitor in these patients did not affect platelet function test at 30 and 60 min, although we could not dismiss some biases in the rest of study timepoints.

This study has some limitations. First, the trial enrolled patients with STEMI, and this fact may limit the generalization to clinical patient population with another cardiovascular disease. Second, the relation between clinical outcomes and the speed of onset and magnitude of platelet inhibition with LA is unknown. Moreover, this study has a small sample size (eventually less patients than those initially planned) and the final results should be considered carefully. Finally, the present study was not designed to evaluate maintenance doses. However, protocol design and statistical analyses reinforced the value of the results obtained, which suggested a pharmacodynamic benefit of intravenous LA compared with oral aspirin.

**Conclusions**

The administration of intravenous LA resulted in a significantly reduction of platelet reactivity compared to oral aspirin on ticagrelor inhibited platelets in patients with STEMI. Loading dose of LA achieves an earlier platelet inhibition, and with less variability than aspirin.

**Funding** This study was supported by the CTU-SCReN (Clinical Trial Unit—Spanish Clinical Research Network) from San Carlos University Hospital (Madrid, Spain), financed by the ISCII (Project PI16/00191). Principal Investigator: David Vivas, MD, PhD.

**Data Availability** The data that support the findings of this study are available on request from the corresponding author, on reasonable request.

**Declarations**

**Conflict of interest** The authors declare that there is no conflict of interest in this manuscript.

**References**

1. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685–1695
2. Davi G, Patrono C (2007) Platelet activation and atherothrombosis. New Engl J Med 357:2482–2494
3. Angiolillo DJ, Ueno M, Goto S (2010) Basic principles of platelet biology and clinical implications. Circ J 74:597–607
5. O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, CF/AHA Task Force et al (2013) 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 127:529–555

8. Matetzky S, Shenkman B, Guetta V, Shechter M, Beinart R, Goldenberg J et al (2004) Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109:3171–3175

10. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Piyawattanametha P, Myler L et al (2013) Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary revascularization for acute coronary syndrome: results from the TRITON-TIMI 38 trial subgroup analysis. Circulation 128:688–698

11. Wallentin L, Becker RC, Budaj A, Cannon CP, Harrington RA, Mehta SR, Filippatos G et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes: an overview of subgroup analyses from the TRITON-TIMI 38 trial. Eur Heart J 30:2193–2213

17. Vivas D, Martin A, Bernardo E, Ortega-Pozzi MA, Tirado G, Fernández C et al (2015) Impact of intravenous lysine acetylsalicylate versus oral aspirin on prasugrel-inhibited platelets: results of a prospective, randomized, crossover study (the ECCLIPSE trial). Circ Cardiovasc Interv 8: pii:002281. https://doi.org/10.1161/CIRCINTERVENTIONS.114.002281

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.